CD44v9 is associated with epithelial-mesenchymal transition and poor outcomes in esophageal squamous cell carcinoma

Daisuke Taniguchi, Hiroshi Saeki, Yuichiro Nakashima, Kensuke Kudou, Ryota Nakanishi, Nobuhide Kubo, Koji Ando, Eiji Oki, Yoshinao Oda, Yoshihiko Maehara

研究成果: ジャーナルへの寄稿記事

抄録

CD44 serves as a marker of cancer stem cells. Alternative splicing generates the CD44v9 isoform. Cancer stem cells are associated with the epithelial-mesenchymal transition in cancers, although little is known about their role in esophageal squamous cell carcinoma. Here, we aimed to clarify the relationship between CD44v9 expression, the epithelial-mesenchymal transition, and clinicopathological features of patients with esophageal squamous cell carcinoma. CD44v9 levels were higher at the tumor invasive front compared with the center of the tumor and higher in metastatic lymph nodes compared with primary tumors. High levels of CD44v9 at the tumor invasive front were significantly associated with deeper tumor invasion and shorter overall survival and recurrence-free survival. The expression of CD44v9 was increased by treatment with transforming growth factor-β, which induced esophageal squamous cell carcinoma cells to undergo the epithelial-mesenchymal transition. Moreover, inhibition of CD44v9 expression decreased the migration and invasiveness of esophageal squamous cell carcinoma cells. These results indicate that the expression of CD44v9 at the tumor invasive front induced by stemness was strongly associated with the epithelial-mesenchymal transition and poor prognosis of patients with esophageal squamous cell carcinoma. CD44v9 may therefore serve as a novel prognostic biomarker and a potential therapeutic target for esophageal squamous cell carcinoma.

元の言語英語
ページ(範囲)6258-6268
ページ数11
ジャーナルCancer Medicine
7
発行部数12
DOI
出版物ステータス出版済み - 12 2018

Fingerprint

Epithelial-Mesenchymal Transition
Neoplasms
Neoplastic Stem Cells
Survival
Alternative Splicing
Transforming Growth Factors
Esophageal Squamous Cell Carcinoma
Protein Isoforms
Biomarkers
Lymph Nodes
Recurrence
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

これを引用

CD44v9 is associated with epithelial-mesenchymal transition and poor outcomes in esophageal squamous cell carcinoma. / Taniguchi, Daisuke; Saeki, Hiroshi; Nakashima, Yuichiro; Kudou, Kensuke; Nakanishi, Ryota; Kubo, Nobuhide; Ando, Koji; Oki, Eiji; Oda, Yoshinao; Maehara, Yoshihiko.

:: Cancer Medicine, 巻 7, 番号 12, 12.2018, p. 6258-6268.

研究成果: ジャーナルへの寄稿記事

Taniguchi, Daisuke ; Saeki, Hiroshi ; Nakashima, Yuichiro ; Kudou, Kensuke ; Nakanishi, Ryota ; Kubo, Nobuhide ; Ando, Koji ; Oki, Eiji ; Oda, Yoshinao ; Maehara, Yoshihiko. / CD44v9 is associated with epithelial-mesenchymal transition and poor outcomes in esophageal squamous cell carcinoma. :: Cancer Medicine. 2018 ; 巻 7, 番号 12. pp. 6258-6268.
@article{b4371c12862f4f76977e466a05a5c297,
title = "CD44v9 is associated with epithelial-mesenchymal transition and poor outcomes in esophageal squamous cell carcinoma",
abstract = "CD44 serves as a marker of cancer stem cells. Alternative splicing generates the CD44v9 isoform. Cancer stem cells are associated with the epithelial-mesenchymal transition in cancers, although little is known about their role in esophageal squamous cell carcinoma. Here, we aimed to clarify the relationship between CD44v9 expression, the epithelial-mesenchymal transition, and clinicopathological features of patients with esophageal squamous cell carcinoma. CD44v9 levels were higher at the tumor invasive front compared with the center of the tumor and higher in metastatic lymph nodes compared with primary tumors. High levels of CD44v9 at the tumor invasive front were significantly associated with deeper tumor invasion and shorter overall survival and recurrence-free survival. The expression of CD44v9 was increased by treatment with transforming growth factor-β, which induced esophageal squamous cell carcinoma cells to undergo the epithelial-mesenchymal transition. Moreover, inhibition of CD44v9 expression decreased the migration and invasiveness of esophageal squamous cell carcinoma cells. These results indicate that the expression of CD44v9 at the tumor invasive front induced by stemness was strongly associated with the epithelial-mesenchymal transition and poor prognosis of patients with esophageal squamous cell carcinoma. CD44v9 may therefore serve as a novel prognostic biomarker and a potential therapeutic target for esophageal squamous cell carcinoma.",
author = "Daisuke Taniguchi and Hiroshi Saeki and Yuichiro Nakashima and Kensuke Kudou and Ryota Nakanishi and Nobuhide Kubo and Koji Ando and Eiji Oki and Yoshinao Oda and Yoshihiko Maehara",
year = "2018",
month = "12",
doi = "10.1002/cam4.1874",
language = "English",
volume = "7",
pages = "6258--6268",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "12",

}

TY - JOUR

T1 - CD44v9 is associated with epithelial-mesenchymal transition and poor outcomes in esophageal squamous cell carcinoma

AU - Taniguchi, Daisuke

AU - Saeki, Hiroshi

AU - Nakashima, Yuichiro

AU - Kudou, Kensuke

AU - Nakanishi, Ryota

AU - Kubo, Nobuhide

AU - Ando, Koji

AU - Oki, Eiji

AU - Oda, Yoshinao

AU - Maehara, Yoshihiko

PY - 2018/12

Y1 - 2018/12

N2 - CD44 serves as a marker of cancer stem cells. Alternative splicing generates the CD44v9 isoform. Cancer stem cells are associated with the epithelial-mesenchymal transition in cancers, although little is known about their role in esophageal squamous cell carcinoma. Here, we aimed to clarify the relationship between CD44v9 expression, the epithelial-mesenchymal transition, and clinicopathological features of patients with esophageal squamous cell carcinoma. CD44v9 levels were higher at the tumor invasive front compared with the center of the tumor and higher in metastatic lymph nodes compared with primary tumors. High levels of CD44v9 at the tumor invasive front were significantly associated with deeper tumor invasion and shorter overall survival and recurrence-free survival. The expression of CD44v9 was increased by treatment with transforming growth factor-β, which induced esophageal squamous cell carcinoma cells to undergo the epithelial-mesenchymal transition. Moreover, inhibition of CD44v9 expression decreased the migration and invasiveness of esophageal squamous cell carcinoma cells. These results indicate that the expression of CD44v9 at the tumor invasive front induced by stemness was strongly associated with the epithelial-mesenchymal transition and poor prognosis of patients with esophageal squamous cell carcinoma. CD44v9 may therefore serve as a novel prognostic biomarker and a potential therapeutic target for esophageal squamous cell carcinoma.

AB - CD44 serves as a marker of cancer stem cells. Alternative splicing generates the CD44v9 isoform. Cancer stem cells are associated with the epithelial-mesenchymal transition in cancers, although little is known about their role in esophageal squamous cell carcinoma. Here, we aimed to clarify the relationship between CD44v9 expression, the epithelial-mesenchymal transition, and clinicopathological features of patients with esophageal squamous cell carcinoma. CD44v9 levels were higher at the tumor invasive front compared with the center of the tumor and higher in metastatic lymph nodes compared with primary tumors. High levels of CD44v9 at the tumor invasive front were significantly associated with deeper tumor invasion and shorter overall survival and recurrence-free survival. The expression of CD44v9 was increased by treatment with transforming growth factor-β, which induced esophageal squamous cell carcinoma cells to undergo the epithelial-mesenchymal transition. Moreover, inhibition of CD44v9 expression decreased the migration and invasiveness of esophageal squamous cell carcinoma cells. These results indicate that the expression of CD44v9 at the tumor invasive front induced by stemness was strongly associated with the epithelial-mesenchymal transition and poor prognosis of patients with esophageal squamous cell carcinoma. CD44v9 may therefore serve as a novel prognostic biomarker and a potential therapeutic target for esophageal squamous cell carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=85057334989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057334989&partnerID=8YFLogxK

U2 - 10.1002/cam4.1874

DO - 10.1002/cam4.1874

M3 - Article

C2 - 30474922

AN - SCOPUS:85057334989

VL - 7

SP - 6258

EP - 6268

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

IS - 12

ER -